Rapid recovery of self-stimulation from depression produced by the atypical neuroleptic risperidone is not prevented by 5-HT2 receptor stimulation

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 4, 1997, Pages 1045-1049

  Grottick, A J ^a,b   Montgomery, A M J ^b   Herberg, L J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

5 HT2 receptors; Alpha2 adrenoceptors; Atypical neuroleptics; DOI; Risperidone; Schizophrenia; Self stimulation

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; RISPERIDONE; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SELF STIMULATION; SUBCUTANEOUS DRUG ADMINISTRATION; VENTRAL TEGMENTUM;

AMPHETAMINES; ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, INBRED STRAINS; RECEPTORS, SEROTONIN; RISPERIDONE; SELF STIMULATION; SEROTONIN AGONISTS;

EID: 0031416088     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00055-5     Document Type: Article

References (26)

1. Agars K., Kokkinidis L. Scopolamine increases nonreinforced behavior in an intracranial self-stimulation discrimination paradigm. Pharmacol. Biochem. Behav. 43:1992;657-660.
2. Balsara J. J., Jadhav J. H., Chandorka A. G. Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berlin). 62:1979;67-69.
3. Bethany S., Neal-Beliveau J. N., Lucki J., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
4. Ettenberg A. Dopamine, antipsychotics and rewarded behaviour. Neurosci. Biobehav. Rev. 3:1989;105-111.
5. Fouriezos G., Wise R. A. Pimozide-induced extinction of intracranial self-stimulation. Response patterns rule out motor or performance deficits Brain Res. 103:1976;377-380.
6. Fowler S. C. Neuroleptics produce within-session response decrements. Facts and theories Drug Dev. Res. 20:1990;101-116.
7. 2-Adrenoceptor antagonism may contribute to the atypical properties of risperidone. Experimental support for the Nutt case J. Psychopharmacol. 9:1995;281-283.
8. Hicks P. B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47:1990;1609-1615.
9. Kane J., Honigfeld G., Singer J., Meltzer H. Y. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry. 45:1988;789-796.
10. 2 antagonism and EPS benefits. Is there a causal connection? Psychopharmacology (Berlin). 124:1996;35-39.
11. Kinon B. H., Lieberman J. A. Mechanisms of action of atypical antipsychotic drugs. A critical analysis Psychopharmacology (Berlin). 124:1996;2-34.
12. 2 receptors Psychopharmacology (Berlin). 112:1993;540-554.
13. 2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
14. 2 antagonist ritanserin. Psychopharmacology (Berlin). 123:1996;98-102.
15. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics? J. Psychopharmacol. 8:1994;193-195.
16. Paxinos G., Watson C. The rat brain in stereotaxic co-ordinates. 2:1986;Academic Press, Sydney.
17. 2 antagonists modulates the effect of D2 dopamine receptor blockade. J. Pharmacol. Exp. Ther. 253:1990;1162-1170.
18. Sanger D. J. Response decrement patterns after antipsychotic and nonantipsychotic drugs. Psychopharmacology (Berlin). 89:1986;98-104.
19. Sanger D. J., Perrault G. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. J. Pharmacol. Exp. Ther. 272:1995;708-713.
20. Schaefer G. J., Michael R. P. Schedule-controlled brain self-stimulation. Has it utility for behavioral pharmacology? Neurosci. Biobehav. Rev. 16:1992;569-583.
21. Schotte A., Janssen P. F. M., Gommeren W., Luyten W. H. M. L., Van Gompel P., Le Sage A. S., De Loore K., Leysen J. E. Risperidone compared with new and reference antipsychotic drugs. In vitro and in vivo receptor binding Psychopharmacology (Berlin). 124:1996;57-73.
22. Stockmeier C. A., DiCarlo J., Zhan Y., Thompson P., Meltzer H. Y. Characterisation of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin-2 and dopamine-2 receptors. J. Pharmacol. Exp. Ther. 2663:1993;1374-1384.
23. 2 receptor binding study of risperidone and haloperidol. Pharmacol. Biochem. Behav. 47:1994;553-557.
24. Vidali M., Fregnan G. B. Effect of different CNS-active drugs on the catalepsy induced by antipsychotics. Curr. Ther. Res. 25:1979;544-556.
25. Wadenberg M. L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural Trans. [Gen. Section]. 89:1992;49-59.
26. Wauquier A. Neuroleptics and self-stimulation. Int. Rev. Neurobiol. 21:1970;335-403.